The latest study will test setidegrasib versus docetaxel in second-line lung cancer.
ApexOnco Front Page
Recent articles
What could be the four HengRui assets picked up by Bristol?
But the company is awaiting pivotal results with TAR-200 in papillary disease before filing.
The curtain lifts on Veritac-2, rusfertide, and another double plenary for Astra.
Skyscraper-07 fails, while a Poseida-originated Car-T is also scrapped.
Can activity at CTLA-4 be added to PD-1 x VEGF blockade?
Meanwhile, the company plays down the risk of Jaypirca’s CLL approval being rescinded.
The PD-1 x VEGF molecule's latest win comes from Akeso's Harmoni-6 trial.